| Multiple Sclerosis, Secondary Progressive
Copaxone vs Mavenclad
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, secondary progressive.Deep comparison between: Copaxone vs Mavenclad with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMavenclad has a higher rate of injection site reactions vs Copaxone based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mavenclad but not Copaxone, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Copaxone
Mavenclad
At A Glance
SC injection
Daily or 3x weekly
Immunomodulator
Oral
2 yearly treatment courses
Nucleoside metabolic inhibitor
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive 20 mg/mL SC once daily OR 40 mg/mL SC three times per week (at least 48 hours apart); the two strengths are not interchangeable.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Cumulative dose of 3.5 mg/kg administered orally, divided into 2 yearly treatment courses (1.75 mg/kg per course); each course consists of 2 cycles of 4 to 5 consecutive days of dosing; no more than 2 tablets (20 mg) per day; do not administer additional treatment during the 2 years following completion of 2 courses.
Contraindications
- Known hypersensitivity to glatiramer acetate or mannitol, including anaphylaxis
- Current malignancy
- Pregnancy, or women or men of reproductive potential not using effective contraception during dosing and for 6 months after the last dose in each treatment course
- HIV infection
- Active chronic infections (e.g., hepatitis or tuberculosis)
- History of hypersensitivity to cladribine
- Breastfeeding on a treatment day and for 10 days after the last dose
Adverse Reactions
Most common (>=2%) Injection site erythema, pain, pruritus, mass, edema, and inflammation; vasodilatation, rash, dyspnea, chest pain, nausea, palpitations, lymphadenopathy, asthenia, anxiety, infection
Serious Anaphylactic reactions, immediate post-injection reaction, chest pain, lipoatrophy and skin necrosis, potential effects on immune response, hepatic injury
Postmarketing Sepsis, SLE syndrome, thrombosis, myocardial infarct, thrombocytopenia, lymphoma-like reaction, acute leukemia, cirrhosis, hepatic injury, anaphylactic reactions, cerebrovascular accident, pulmonary embolus, blindness
Most common (>20%) Upper respiratory tract infection, headache, lymphopenia
Serious Malignancies, teratogenicity, lymphopenia, infections, hematologic toxicity, graft-versus-host disease with blood transfusion, liver injury, hypersensitivity, cardiac failure, seizures, myelodysplastic syndrome
Postmarketing Nocardiosis, varicella zoster, histoplasmosis, cryptococcosis, toxoplasmosis, liver injury
Pharmacology
Glatiramer acetate is an immunomodulator thought to act by modifying immune processes responsible for MS pathogenesis; upon SC administration, glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery.
Cladribine is a nucleoside metabolic inhibitor that exerts cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes; this lymphocyte-depleting mechanism is thought to underlie its therapeutic effects in relapsing forms of multiple sclerosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Copaxone
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (1/12) · Qty limit (11/12)
Mavenclad
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Copaxone
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (7/8)
Mavenclad
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Copaxone
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Mavenclad
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CopaxoneView full Copaxone profile
MavencladView full Mavenclad profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.